Tebapivat

DB19338InvestigationalSmall molecule

Tebapivat is under investigation in clinical trial NCT05490446 (A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-risk Myelodysplastic Syndromes (LR-MDS)).

Mechanism: Pharmacologically active on Pyruvate kinase PKLR and Pyruvate Kinases
Curator reviewed
Formula / weight: C₁₈H₁₆N₈OS · 392.44 g/mol (avg)
Also known as: 6-[(6-aminopyridin-2-yl)methyl]-4-methyl-2-[(1H-pyrazol-3-yl)methyl]-4,6-dihydro-5H-[1,3]thiazolo[5',4':4,5]pyrrolo[2,3-d]pyridazin-5-one
Code names: AG-946 · CS-0115951 · HY-135884

Resolves to

Compound

UNIIORG4KGP5ZSChEMBLCHEMBL5314542ChEBI759243PubChem137501615

Structure

InChIKeyDIUOELXIXSCFCR-UHFFFAOYSA-NSMILESCN1C2=C(SC(CC3=NNC=C3)=N2)C2=C1C(=O)N(CC1=CC=CC(N)=N1)N=C2

Targets

P30613PKLR

What you can answer from here — as of September 23, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tebapivat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account